Research Keyword: psychedelic research

Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial

mycolabadmin

Researchers conducted a small pilot study examining whether psilocybin (the active compound in certain mushrooms) combined with therapy could help treat fibromyalgia, a chronic pain condition. Five participants received two doses of psilocybin along with supportive therapy sessions. The treatment was well-tolerated with only minor side effects, and participants reported significant improvements in pain, sleep quality, and overall functioning. These promising preliminary results suggest larger studies should be conducted to further test this innovative treatment approach.

Read More »

Postpartum depression: A role for psychedelics?

mycolabadmin

Postpartum depression affects many new mothers and involves feelings of disconnection from themselves and their babies. This review suggests that psilocybin, the active compound in psychedelic mushrooms, might help by promoting reconnection and acceptance. The authors examine safety data suggesting psilocybin could potentially be used safely in postpartum women if appropriate precautions are taken, such as temporarily stopping breastfeeding after treatment.

Read More »

Psychedelics: Safety and Efficacy

mycolabadmin

This paper reviews scientific research on psychedelic drugs like LSD and psilocybin that are being studied for treating depression and PTSD. While some research claims these drugs are beneficial, many studies have serious flaws including hiding negative side effects and being influenced by money from pharmaceutical companies. The author concludes that we need much better research before these drugs can be safely approved for medical use.

Read More »

Further education in psychedelic-assisted therapy – experiences from Switzerland

mycolabadmin

As psychedelic drugs show promise in treating serious mental health conditions like depression and PTSD, there is growing need to train therapists to safely administer these novel treatments. Switzerland’s leading medical association has developed a comprehensive three-year training program that combines classroom learning with hands-on practice to prepare doctors and psychologists. The program faces overwhelming demand, with far more people wanting to train than available spots, highlighting the urgent need for more specialized education programs as these treatments potentially become mainstream medications.

Read More »
Scroll to Top